Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program☆
Background - Circulating tumor cells (CTCs) have been reported to predict clinical outcome in metastatic breast cancer (MBC). Biology of CTCs may differ from that of the primary tumor and HER2-positive CTCs are found in some patients with HER2-negative tumors. - Patients and methods - Patients with...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
25 November 2021
|
| In: |
ESMO open
Year: 2021, Jahrgang: 6, Heft: 6, Pages: 1-8 |
| ISSN: | 2059-7029 |
| DOI: | 10.1016/j.esmoop.2021.100299 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.esmoop.2021.100299 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S2059702921002611 
|
| Verfasserangaben: | V. Müller, M. Banys-Paluchowski, T.W.P. Friedl, P.A. Fasching, A. Schneeweiss, A. Hartkopf, D. Wallwiener, B. Rack, F. Meier-Stiegen, J. Huober, M. Rübner, O. Hoffmann, L. Müller, W. Janni, P. Wimberger, B. Jäger, K. Pantel, S. Riethdorf, N. Harbeck & T. Fehm, on behalf of DETECT study group |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1828240516 | ||
| 003 | DE-627 | ||
| 005 | 20230426192913.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221221s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.esmoop.2021.100299 |2 doi | |
| 035 | |a (DE-627)1828240516 | ||
| 035 | |a (DE-599)KXP1828240516 | ||
| 035 | |a (OCoLC)1361713394 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Müller, Volkmar |d 1967- |e VerfasserIn |0 (DE-588)12133497X |0 (DE-627)081238053 |0 (DE-576)292653719 |4 aut | |
| 245 | 1 | 0 | |a Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program☆ |c V. Müller, M. Banys-Paluchowski, T.W.P. Friedl, P.A. Fasching, A. Schneeweiss, A. Hartkopf, D. Wallwiener, B. Rack, F. Meier-Stiegen, J. Huober, M. Rübner, O. Hoffmann, L. Müller, W. Janni, P. Wimberger, B. Jäger, K. Pantel, S. Riethdorf, N. Harbeck & T. Fehm, on behalf of DETECT study group |
| 264 | 1 | |c 25 November 2021 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 20.12.2022 | ||
| 520 | |a Background - Circulating tumor cells (CTCs) have been reported to predict clinical outcome in metastatic breast cancer (MBC). Biology of CTCs may differ from that of the primary tumor and HER2-positive CTCs are found in some patients with HER2-negative tumors. - Patients and methods - Patients with HER2-negative MBC were screened for participation in DETECT III and IV trials before the initiation of a new line of therapy. Blood samples were analyzed using CELLSEARCH. CTCs were labeled with an anti-HER2 antibody and classified according to staining intensity (negative, weak, moderate, or strong staining). - Results - Screening blood samples were analyzed in 1933 patients with HER2-negative MBC. As many as 1217 out of the 1933 screened patients (63.0%) had ≥1 CTC per 7.5 ml blood; ≥5 CTCs were detected in 735 patients (38.0%; range 1-35 078 CTCs, median 8 CTCs). HER2 status of CTCs was assessed in 1159 CTC-positive patients; ≥1 CTC with strong HER2 staining was found in 174 (15.0%) patients. The proportion of CTCs with strong HER2 staining among all CTCs of an individual patient ranged between 0.06% and 100% (mean 15.8%). Patients with estrogen receptor (ER)- and progesterone receptor (PR)-positive tumors were more likely to harbor ≥1 CTC with strong HER2 staining. CTC status was significantly associated with overall survival (OS). Detection of ≥1 CTC with strong HER2 staining was associated with shorter OS [9.7 (7.1-12.3) versus 16.5 (14.9-18.1) months in patients with CTCs with negative-to-moderate HER2 staining only, P = 0.013]. In multivariate analysis, age, ER status, PR status, Eastern Cooperative Oncology Group performance status, therapy line, and CTC status independently predicted OS. - Conclusion - CTC detection in patients with HER2-negative disease is a strong prognostic factor. Presence of ≥1 CTC with strong HER2 staining was associated with shorter OS, supporting a biological role of HER2 expression on CTCs. | ||
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a circulating tumor cell | |
| 650 | 4 | |a HER2 status | |
| 650 | 4 | |a liquid biopsy | |
| 650 | 4 | |a survival | |
| 700 | 1 | |a Banys-Paluchowski, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Friedl, T. W. P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fasching, P. A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schneeweiss, Andreas |d 1961- |e VerfasserIn |0 (DE-588)109972554 |0 (DE-627)632849630 |0 (DE-576)327251859 |4 aut | |
| 700 | 1 | |a Hartkopf, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wallwiener, D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rack, B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Meier-Stiegen, F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Huober, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rübner, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hoffmann, O. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Müller, L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Janni, W. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wimberger, P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jäger, B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pantel, K. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Riethdorf, S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Harbeck, N. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fehm, T. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ESMO open |d [London] : Elsevier, 2016 |g 6(2021), 6, Artikel-ID 100299, Seite 1-8 |h Online-Ressource |w (DE-627)84705344X |w (DE-600)2844985-X |w (DE-576)454658516 |x 2059-7029 |7 nnas |a Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program☆ |
| 773 | 1 | 8 | |g volume:6 |g year:2021 |g number:6 |g elocationid:100299 |g pages:1-8 |g extent:8 |a Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program☆ |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.esmoop.2021.100299 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S2059702921002611 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20221221 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 109972554 |a Schneeweiss, Andreas |m 109972554:Schneeweiss, Andreas |d 910000 |d 910400 |d 50000 |e 910000PS109972554 |e 910400PS109972554 |e 50000PS109972554 |k 0/910000/ |k 1/910000/910400/ |k 0/50000/ |p 5 | ||
| 999 | |a KXP-PPN1828240516 |e 4237311740 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"name":{"displayForm":["V. Müller, M. Banys-Paluchowski, T.W.P. Friedl, P.A. Fasching, A. Schneeweiss, A. Hartkopf, D. Wallwiener, B. Rack, F. Meier-Stiegen, J. Huober, M. Rübner, O. Hoffmann, L. Müller, W. Janni, P. Wimberger, B. Jäger, K. Pantel, S. Riethdorf, N. Harbeck & T. Fehm, on behalf of DETECT study group"]},"recId":"1828240516","person":[{"display":"Müller, Volkmar","given":"Volkmar","role":"aut","family":"Müller"},{"role":"aut","family":"Banys-Paluchowski","given":"M.","display":"Banys-Paluchowski, M."},{"role":"aut","family":"Friedl","display":"Friedl, T. W. P.","given":"T. W. P."},{"family":"Fasching","role":"aut","display":"Fasching, P. A.","given":"P. A."},{"family":"Schneeweiss","role":"aut","display":"Schneeweiss, Andreas","given":"Andreas"},{"role":"aut","family":"Hartkopf","display":"Hartkopf, A.","given":"A."},{"display":"Wallwiener, D.","given":"D.","family":"Wallwiener","role":"aut"},{"role":"aut","family":"Rack","given":"B.","display":"Rack, B."},{"display":"Meier-Stiegen, F.","given":"F.","role":"aut","family":"Meier-Stiegen"},{"family":"Huober","role":"aut","given":"J.","display":"Huober, J."},{"given":"M.","display":"Rübner, M.","family":"Rübner","role":"aut"},{"family":"Hoffmann","role":"aut","display":"Hoffmann, O.","given":"O."},{"given":"L.","display":"Müller, L.","family":"Müller","role":"aut"},{"family":"Janni","role":"aut","display":"Janni, W.","given":"W."},{"given":"P.","display":"Wimberger, P.","role":"aut","family":"Wimberger"},{"display":"Jäger, B.","given":"B.","family":"Jäger","role":"aut"},{"family":"Pantel","role":"aut","display":"Pantel, K.","given":"K."},{"family":"Riethdorf","role":"aut","display":"Riethdorf, S.","given":"S."},{"display":"Harbeck, N.","given":"N.","role":"aut","family":"Harbeck"},{"display":"Fehm, T.","given":"T.","role":"aut","family":"Fehm"}],"note":["Gesehen am 20.12.2022"],"title":[{"title_sort":"Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program☆","title":"Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program☆"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"physDesc":[{"extent":"8 S."}],"id":{"eki":["1828240516"],"doi":["10.1016/j.esmoop.2021.100299"]},"relHost":[{"name":{"displayForm":["European Society for Medical Oncology"]},"recId":"84705344X","title":[{"title_sort":"ESMO open","subtitle":"cancer horizons","title":"ESMO open"}],"id":{"issn":["2059-7029"],"eki":["84705344X"],"zdb":["2844985-X"]},"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedKey":"2016","publisherPlace":"[London] ; London","publisher":"Elsevier ; BMJ","dateIssuedDisp":"2016-"}],"language":["eng"],"part":{"volume":"6","year":"2021","extent":"8","pages":"1-8","issue":"6","text":"6(2021), 6, Artikel-ID 100299, Seite 1-8"},"note":["Gesehen am 13.06.24"],"pubHistory":["1.2016 -"],"corporate":[{"role":"isb","display":"European Society for Medical Oncology"}],"disp":"Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program☆ESMO open","type":{"bibl":"periodical","media":"Online-Ressource"}}],"origin":[{"dateIssuedDisp":"25 November 2021","dateIssuedKey":"2021"}]} | ||
| SRT | |a MUELLERVOLPROGNOSTIC2520 | ||